Provided by Tiger Fintech (Singapore) Pte. Ltd.

Century Therapeutics, Inc.

0.4723
+0.00781.68%
Post-market: 0.4576-0.0147-3.11%19:31 EST
Volume:988.65K
Turnover:460.98K
Market Cap:40.80M
PE:-1.73
High:0.4849
Open:0.4800
Low:0.4510
Close:0.4645
52wk High:1.83
52wk Low:0.3418
Shares:86.39M
Float Shares:45.36M
Volume Ratio:0.90
T/O Rate:2.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2733
EPS(LYR):-1.6093
ROE:-10.78%
ROA:-5.11%
PB:0.19
PE(LYR):-0.29

Loading ...

Century Therapeutics Q3 net loss widens, despite lower costs

Reuters
·
Nov 13

Century Therapeutics reports Q3 EPS (40c) vs (37c) last year

TIPRANKS
·
Nov 13

Century Therapeutics Q3 EPS $(0.40) Misses $(0.34) Estimate

Benzinga
·
Nov 13

BRIEF-Century Therapeutics Q3 Net Income USD -34.422 Million

Reuters
·
Nov 13

Century Therapeutics Q3 Operating Income USD -36.124 Million

THOMSON REUTERS
·
Nov 13

Century Therapeutics Inc - Estimates Cash Runway Into 4Q 2027

THOMSON REUTERS
·
Nov 13

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 13

Century Therapeutics Reports Preclinical Success for Immune-Evasive Beta Islet Therapy in Type 1 Diabetes

Reuters
·
Nov 13

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

THOMSON REUTERS
·
Nov 13

Century Therapeutics Inc - Ind-Enabling Studies to Start by Year-End 2025, Ind Submission Planned as Early as 2026

THOMSON REUTERS
·
Nov 13

Top News Today/Canada: Barrick's Interim CEO Gets to Work

Dow Jones
·
Nov 11

Century Therapeutics’ CALiPSO-1 Study: A Promising Step in Autoimmune Disease Treatment

TIPRANKS
·
Oct 28

Century Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
Oct 24

Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference

GlobeNewswire
·
Oct 15

Century Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Non-Compliance with Minimum Bid Price Rule

Reuters
·
Aug 30

Century Therapeutics Inc - Brent Pfeiffenberger Appointed Chairman of the Board - SEC Filing

THOMSON REUTERS
·
Aug 15

Century Therapeutics Inc - Cash Runway Extended Into Fourth Quarter 2027 - SEC Filing

THOMSON REUTERS
·
Aug 15

BRIEF-Century Therapeutics Q2 Net Income USD -32.541 Million

Reuters
·
Aug 15

Century Therapeutics Inc - Cash Runway Extended Into Q4 2027

THOMSON REUTERS
·
Aug 15

Century Therapeutics Q2 Operating Expenses USD 34.664 Million

THOMSON REUTERS
·
Aug 15